Appeared before AFI panel for dope offence in 2008: Maheswary

Image
Press Trust of India New Delhi
Last Updated : Sep 19 2013 | 9:46 PM IST
Triple jumper Renjith Maheswary, who was today denied Arjuna Award by the Sports Ministry for flunking a dope test in 2008, admitted that he had appeared before an enquiry panel of the Athletics Federation of India at that time for returning positive for a banned drug.
"I had taken medicine for cold and cough prescribed by my local doctor in Kerala and that had led to the result (positive for ephedrine) in my urine sample. I was told by the AFI to appear before its enquiry committee in 2008 and furnish all the documents and certificates how the banned drug had entered into my system," Maheswary told PTI from Chennai.
"I appeared before the AFI enquiry panel and submitted the prescription and certificate of my local doctor that I was suffering from cold and cough and I had taken medicine for that," said Meheswary, who in 2008 represented Kerala and later shifted base in Tamil Nadu.
The 27-year-old said he had furnished information while giving his urine sample that he was suffering from cold and cough and so he was taking medicines.
The Sports Ministry in a release said that Maheswary had not reported using ephedrine for medicinal purposes during the collection of the sample.
The Sports Ministry also said that Maheswary was communicated by the Director of AFI on January 10, 2009 that he had been handed three months suspension for a dope offence.
Maheswary, however, maintained that he was not informed by any authority, including the AFI, that he was banned for three months for dope offence.
"I was not informed by anybody, including the AFI, about a three-month ban. I appeared before the AFI panel and I was told I had committed some wrong. I put my case that the drug had entered into my body due to the use of medicines I took for my cough and cold. That was it. Nobody told me about the suspension later on," he said.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 19 2013 | 9:46 PM IST

Next Story